Adenovirus/psa vaccine - a cancer vaccine composed of a genetically engineered, replication-deficient type 5 adenovirus carrying the human prostate-specific antigen (psa), with potential immunostimulating and antineoplastic activities. Upon subcutaneous vaccination with the adenovirus-psa prostate cancer vaccine, the adenovirus infects cells and expresses psa. In turn, psa may activate the immune system and may induce a cytotoxic t-lymphocyte response against psa-expressing tumor cells. Psa, a tumor associated antigen, is expressed by prostate epithelial cells and is overexpressed in prostate cancer. Also see adenovirus-psa prostate cancer vaccine
Up to date info
Latest research - Adenovirus/psa vaccine
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on Adenovirus/psa vaccine for any updates.